How many health authorities and professionals recommended pregnant women take the experimental COVID-19 jab?
The medical establishment widely recommended the experimental mRNA gene therapy for pregnant women.
Here are just a couple of examples.
COVID-19 vaccination is recommended for all people aged 6 months and older. This includes people who are pregnant, breastfeeding, trying to get pregnant now, or those who might become pregnant in the future.
The American College of Obstetricians and Gynecologists (ACOG):
The American College of Obstetricians and Gynecologists (ACOG) strongly recommends that pregnant individuals be vaccinated against COVID-19. Given the potential for severe illness and death during pregnancy, completion of the initial COVID-19 vaccination series is a priority for this population.
Doesn’t the medical establishment constantly repeat ‘Follow the Science?’
Here’s the thing.
The recommendation for pregnant women to receive the COVID-19 jab wasn’t backed by any data whatsoever.
It was pure propaganda.
Pfizer initiated a clinical trial to monitor the safety and efficacy of its COVID-19 mRNA gene therapy in pregnant women in February 2021.
However, Pfizer hasn’t published the results from that clinical trial.
Dr. Marty Makary explained:
In a shocking admission, Pfizer said it stopped the COVID-19 jab clinical trial for pregnant women.
Investigative journalist Maryanne Demasi reached out to Pfizer for answers and she received a response from the Pharma giant.
Demasi wrote in her substack newsletter:
In response to my questions, today I can reveal the reason why Pfizer hasn’t published the study — the company admitted it does not have the data.
In an email, Pfizer said the trial’s “enrollment rate declined significantly” towards the end of 2021, because authorities had already widely recommended the vaccine to pregnant women.
Declining enrollments meant that there were insufficient numbers of participants in the trial to carry out the intended analysis.
Pfizer’s full response:
In the fourth quarter of 2021, enrollment was stopped in C4591015 Study (a Phase 2/3 placebo controlled randomized observer-blind study to evaluate the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19 in healthy pregnant women 18 years of age and older). This study was developed prior to availability or recommendation for COVID-19 vaccination in pregnant women. The environment changed during 2021 and by September 2021, COVID-19 vaccines were recommended by applicable recommending bodies (e.g., ACIP in the U.S.) for pregnant women in all participating/planned countries, and as a result the enrollment rate declined significantly. With the declining enrollment, the study had insufficient sample size to assess the primary immunogenicity objective and continuation of this placebo controlled study could no longer be justified due to global recommendations. This proposal was shared with and agreed to by FDA and EMA.
Pfizer does not yet have a complete data set from the maternal immunization study, C4591015. Pfizer and BioNTech plan to complete the analysis of the clinical trial C4591015 and share it with global public health regulators and seek publication or presentation as is our standard practice. It is important to note that relevant real-world evidence on the use of COVID-19 vaccines in pregnant women has been presented and published numerous times by various parties in multiple journals and forums.
Despite admitting it doesn’t have the data, Pfizer listed the study in 2022 as complete.
Zero Hedge noted:
An internal email, disclosed in a court case, previously indicated Pfizer had stopped enrollment early.
“The study enrolment was stopped with incomplete numbers because recruitment was slow and it became unreasonable/inappropriate to randomise pregnant women to placebo given the amount of observational evidence that the vaccine is safe and effective, coupled with increasing number of technical committees supporting immunization of pregnant women,” Jelena Vojicic, vaccines medical lead at Pfizer Canada, wrote in the 2022 email.
The randomized, placebo-controlled study in question was launched in early 2021 after pregnant women were excluded from the phase three trial that led to the authorization of the vaccine in the United States and a number of other countries.
Pfizer and BioNTech said they expected to enroll some 4,000 pregnant women but actually enrolled just 349, according to the trial record. Some of the participants were to receive a vaccine while others would receive a placebo, according to the original protocol. Women were expected to be studied for seven to 10 months.
The trial was listed as completed on Aug. 23, 2022, but no results have been released yet.
How many pregnant women have received the COVID-19 jab believing the misinformation that it was ‘safe and effective?’